Axitinib (AG 013736)

A benzamide and indazole derivative that acts as a TYROSINE KINASE inhibitor of the VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR. It is used in the treatment of advanced RENAL CELL CARCINOMA.

Also Known As:

Networked: 800 relevant articles (122 outcomes, 270 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Rini, Brian I: 38 articles (10/2022 - 12/2005)
2.	Kim, Sinil: 28 articles (08/2015 - 11/2007)
3.	Rosbrook, Brad: 22 articles (10/2021 - 09/2009)
4.	Choueiri, Toni K: 17 articles (10/2022 - 06/2008)
5.	Motzer, Robert J: 16 articles (10/2022 - 11/2007)
6.	Tarazi, Jamal: 16 articles (01/2019 - 09/2009)
7.	Albiges, Laurence: 15 articles (10/2022 - 02/2014)
8.	Escudier, Bernard: 15 articles (06/2020 - 01/2011)
9.	Pithavala, Yazdi K: 15 articles (12/2016 - 08/2005)
10.	Bycott, Paul: 15 articles (05/2015 - 07/2006)

Related Diseases

1.	Renal Cell Carcinoma (Grawitz Tumor) 11/01/2016 - "Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study." 01/01/2021 - "Efficacy of axitinib rechallenge in metastatic renal cell carcinoma." 08/01/2020 - "Baseline LDH, neutrophil, Ca, Plt and time from diagnosis are predictive factors for both PFS and OS in first-line treatment with axitinib for metastatic renal cell carcinoma." 08/01/2020 - "The efficacy of axitinib as a first-line treatment for metastatic renal cell carcinoma." 05/01/2019 - "Following first-line treatment progression in metastatic renal carcinoma, different options for second-line treatment are available, with axitinib being one of them. "
2.	Neoplasms (Cancer) 09/01/2021 - "Targeting the pro-angiogenic pathway in AD using the cancer drug, Axitinib, dramatically reduced cerebrovascular neoangiogenesis, restored BBB integrity, resolved tight-junction pathogenesis, diminishes Aβ depositions in plaques and effectively restores memory and cognitive performance in a preclinical mouse model of AD. " 10/01/2023 - "The combination of BRAF inhibition and axitinib significantly inhibited tumor growth and was associated with improved survival in an orthotopic ATC model. " 01/01/2018 - "Mechanistically, a significant reduction of immune-suppressive cells, including a decrease of tumor-promoting mast cells and tumor-associated macrophages was observed upon axitinib treatment. " 04/01/2015 - "In vivo treatment with axitinib induced a strong inhibition of tumor growth and significantly improved survival in both tumor models. " 04/01/2014 - "Axitinib radiosensitizes tumor endothelial cells and enhances tumor cure with SDRT, which may permit dose de-escalation and significantly expand the range of clinical indications for SDRT."
3.	Colorectal Neoplasms (Colorectal Cancer) 01/01/2018 - "A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer." 01/01/2018 - "The aim of this study was to evaluate the efficacy and safety of maintenance therapy with axitinib versus placebo following induction therapy in patients with metastatic colorectal cancer (mCRC). " 12/02/2022 - "The selective and potent VEGFR inhibitor axitinib was most effective against BRAF-mutant colorectal cancer cell lines in vitro, but the addition of vemurafenib did not significantly increase these effects. " 01/01/2010 - "Important preclinical and clinical data for axitinib are presented including findings from phase II studies in many tumor types including malignant melanoma and renal, pancreatic, thyroid, breast, lung and colorectal carcinomas. " 07/03/2017 - "This phase-2 trial evaluated the efficacy of axitinib as maintenance therapy for patients with metastatic colorectal cancer (mCRC) following first-line treatment with FOLFOX/bevacizumab. "
4.	Melanoma (Melanoma, Malignant) 10/01/2021 - "Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma." 04/01/2015 - "Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model." 12/01/2011 - "Axitinib was well tolerated, showed a selective VEGFR-inhibitory profile, and showed single-agent activity in metastatic melanoma. " 10/01/2021 - "Patients with advanced mucosal melanoma received an anti-PD-1 antibody plus the VEGFR inhibitor axitinib until confirmed disease progression or unacceptable toxicity. " 12/01/2014 - "The final analysis indicated that the pharmacokinetic model for mRCC was able to successfully describe axitinib pharmacokinetics in patients with NSCLC, thyroid cancer, and melanoma. "
5.	Neoplasm Metastasis (Metastasis) 09/01/2018 - "Axitinib as second-line treatment is effective for patients with pulmonary metastasis alone of RCC, but not for those with extrapulmonary metastasis." 01/01/2019 - "The incidence of cutaneous adverse events were low which had been reported by previous studies; however, it is difficult to say that axitinib is a more effective treatment modality for RCC with nasal metastases, which requires further studies." 05/26/2023 - "Postoperatively, the patient was treated transorally with axitinib (10 mg/day) and as of 12 months he remains alive with unchanging lung metastasis. " 01/01/2021 - "Among the patients who achieved a CR, one experienced cerebellar metastasis 18.8 months after discontinuation, but achieved CR again after localized gamma knife and 1-month axitinib treatment. " 06/10/2019 - "Unfortunately, multiple liver metastases were confirmed 1 month after surgery, so axitinib was given but failed immediately. "

Related Drugs and Biologics

1.	pembrolizumab
2.	Sunitinib (Sutent)
3.	avelumab
4.	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
5.	Nivolumab
6.	Tyrosine Kinase Inhibitors
7.	Sorafenib (BAY 43-9006)
8.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
9.	Ipilimumab
10.	Immune Checkpoint Inhibitors

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Immunotherapy
4.	Nephrectomy
5.	Aftercare (After-Treatment)